Research
FDA-approved products vs. RUO compounds
The regulatory, chemical, and supply-chain differences between an FDA-approved medicine and a research-use-only vial with the same molecular name.
- Last updated:
- 2026-07-22
Overview
Some molecules on Healthy Mango exist in both approved and research-supply forms. Semaglutide is FDA-approved as Ozempic and Wegovy; tirzepatide is approved as Mounjaro and Zepbound; bremelanotide is approved as Vyleesi. Each also exists as an RUO vial in the research-supply channel.
The two forms share a chemical name and, in principle, the same peptide sequence. They differ in almost everything else: manufacturing standard, packaging, testing, labelling, distribution, prescribing framework, and what a regulator has actually reviewed.
Why it matters
The strongest argument some readers make for using an RUO vial is "but the molecule is FDA-approved." That argument mistakes an approval of one product for an approval of a different product that shares a name.
Key concepts
Approval is product-specific
The FDA approves products, not molecules. "Wegovy is approved" does not mean "any semaglutide-labelled vial is approved."
Manufacturing chain differs
An approved medicine is manufactured under pharmaceutical Good Manufacturing Practice with documented batch testing. An RUO vial is not necessarily manufactured under those standards.
Labelling and dose
An approved product carries specific concentration, delivery-device, and dosing information. An RUO vial carries a mass label; concentration and dose depend entirely on the reconstitution the end user performs.
Common misconceptions
- "FDA-approved somewhere means safe everywhere." Approval is per-jurisdiction, per-indication, per-product.
- "Generic and RUO are the same." No — a generic is an approved medicine with demonstrated equivalence to the reference; an RUO is not.
- "The RUO version is chemically identical." It may or may not be — identity tests on a specific batch confirm it for that batch, not universally.
Practical interpretation
Where a compound page references an FDA-approved product, treat that reference as scientific and regulatory context, not as an endorsement of the RUO vial for the same molecule.
Limitations
The distinction between approved and RUO is legal and practical. It does not resolve whether either form is appropriate for a specific reader; that is a clinical question outside the scope of the site.